KEY TAKEAWAYSLong-time Tesla bull Dan Ives, an analyst at Wedbush Securities, says Elon Musk is the only one who can turn the ...

Fintel reports that on March 20, 2025, Wedbush initiated coverage of Zenas BioPharma (NasdaqGS:ZBIO) with a Outperform ...

Wedbush issued their FY2029 earnings estimates for Ovid Therapeutics in a note issued to investors on Wednesday, March 12th.

Wedbush LOS ANGELES, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Wedbush, a Los Angeles-based financial services firm with global reach, and a legacy of innovation and client-focused investment solutions ...

Despite the recent sell-off in tech stocks, analysts at Wedbush believe that this downturn is temporary and that AI leaders ...

Overall, Wall Street analysts have deemed NVDA stock a “Strong Buy,” with an average price target of $176.56, which indicates a notable upside potential of 45.1% from the March 14 closing price. Among ...

And Wedbush Securities says their enthusiasm is very much warranted. Analyst Daniel Ives writes that recent supply-chain checks suggest a "normal" launch for the latest iteration of Apple's wildly ...

Tesla (TSLA, $845.00) stock has the potential to reach $950 per share, says Wedbush analyst Daniel Ives. But he still doesn’t think you should buy it. The 11 Best Growth Stocks to Buy for 2021 ...

Could the Apple Car be launched in the foreseeable future? Here is what Wedbush’s Dan Ives had to say about the new product, and what it might mean for Apple stock. When I chatted with Wedbush ...

Delays in AI improvements and the next-generation Siriwhich are currently anticipated with iPhone 17have put pressure on Apple shares, claims Wedbush analyst Daniel Ives. A sluggish tech ...

Wedbush has a “Outperform” rating and a $13.00 price objective on the stock. The consensus estimate for Vigil Neuroscience’s current full-year earnings is ($2.07) per share. Get Vigil ...